Madri­gal’s got more pos­i­tive da­ta for resme­tirom, plus news from Ali­gos and North­Sea

Last year
R&D

Vor shares new da­ta for stem cell ther­a­py; Melin­ta part­ners with Ve­na­torx on an­tibi­ot­ic un­der FDA re­view

Last year
News Briefing

Ther­mo Fish­er plans to lay off 97 em­ploy­ees, close fa­cil­i­ty in Al­aba­ma

Last year
People
Manufacturing

Madri­gal builds on liv­er dis­ease aware­ness cam­paigns as it awaits FDA de­ci­sion on NASH drug resme­tirom

Last year
Pharma
Marketing

Neu­ro­crine ax­es Take­da-part­nered de­pres­sion pro­gram, switch­es fo­cus for seizure drug af­ter PhII fail­ures

Last year
R&D

No­vo in­vests $6B+ to ex­pand man­u­fac­tur­ing fa­cil­i­ties as de­mand for We­govy sky­rock­ets

Last year
Pharma
Cell/Gene Tx

Cen­tu­ry Ther­a­peu­tics nabs Bris­tol My­ers alum as CEO; En­her­tu star Dai­ichi Sankyo makes changes in Eu­rope

Last year
Peer Review

Val­ne­va re­ceives first chikun­gun­ya vac­cine ap­proval af­ter two month de­lay to FDA re­view

Last year
R&D
FDA+

CAR­GO's $281M IPO could be the last list­ing of 2023 af­ter mar­ket's 'dras­tic turn'

Last year
Financing
Startups

Il­lu­mi­na ex­pects rev­enue drop af­ter an­oth­er guid­ance cut

Last year
Diagnostics

How the price of Lil­ly's weight man­age­ment drug could fu­el its ri­val­ry with No­vo Nordisk

Last year
Pharma

FDA ap­proves Takeda's new en­zyme re­place­ment ther­a­py for rare blood clot­ting dis­or­der

Last year
FDA+

ADF asks SCO­TUS not to take up mifepri­s­tone case as Dan­co, DOJ say ar­gu­ments don't hold up

Last year
Pharma
FDA+

Ot­su­ka TV and ban­ner ads for Rex­ul­ti draw re­buke from FDA watch­dog

Last year
Pharma
Marketing

How Boehringer In­gel­heim and Pfiz­er bat­tled over the ex­clu­siv­i­ty of the first Hu­mi­ra in­ter­change­able

Last year
FDA+

Ar­genx pod­cast se­ries fo­cused on a rare dis­ease draws wide au­di­ence amid plans for sec­ond sea­son

Last year
Marketing

Cam­brex sells drug prod­uct busi­ness; Land­mark to work with Gala­pa­gos; Genezen locks $18.5M eq­ui­ty boost 

Last year
Manufacturing

Com­mer­cial-stage man­u­fac­tur­ing key for CD­MOs as biotech fund­ing pull­back con­tin­ues, Fu­ji­film Diosynth CEO says

Last year
Manufacturing

As­traZeneca de­tails ex­pan­sive com­bo strat­e­gy for new oral GLP-1 as ex­ecs wa­ger obe­si­ty mar­ket is ‘here to stay’

Last year
Pharma

No­var­tis plans BTK in­hibitor fil­ing in chron­ic spon­ta­neous ur­ticaria as Celldex’s mid-stage da­ta ex­cite in­vestors

Last year
R&D

Re­genxbio looks to part­ner neu­rode­gen­er­a­tive gene ther­a­py work, lays off 15% of staff

Last year
People
Cell/Gene Tx

Mer­ck KGaA tem­pers 2023 sales ex­pec­ta­tions af­ter un­der­whelm­ing third-quar­ter per­for­mance

Last year
Pharma

In­tel­lia plans to file IND for AATD tri­al next year; As­cid­i­an rais­es $40M

Last year
News Briefing

Re­cur­sion and Bay­er to wind down fi­bro­sis R&D pact af­ter three years, re­fo­cus­ing on can­cer

Last year
Deals
R&D
First page Previous page 247248249250251252253 Next page Last page
A service from the Financial Times